NAOV Stock Overview Through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
NanoVibronix, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for NanoVibronix Historical stock prices Current Share Price US$0.50 52 Week High US$1.52 52 Week Low US$0.44 Beta 1.64 1 Month Change -13.82% 3 Month Change -8.93% 1 Year Change -41.18% 3 Year Change -97.01% 5 Year Change -99.14% Change since IPO -99.29%
Recent News & Updates
NanoVibronix Advances Development of PainShield and UroShield with Completion of NextGen Prototypes Jan 08
NanoVibronix, Inc. Announces Completion of Pilot Phase of Clinical Study of UroShield at the University of Michigan Jan 06
NanoVibronix Receives an Additional Deficiency Notice from Nasdaq Due to Non-Compliance with $2.5 Million Stockholders’ Equity Requirement Nov 24
Third quarter 2024 earnings released: US$0.36 loss per share (vs US$0.42 loss in 3Q 2023) Nov 17
Nasdaq Notifies NanoVibronix Regarding Potential Delisting Due to Non-Compliance with Nasdaq Listing Rule 5550(a)(2) Oct 14
NanoVibronix, Inc., Annual General Meeting, Dec 19, 2024 Oct 08 See more updates
NanoVibronix Advances Development of PainShield and UroShield with Completion of NextGen Prototypes Jan 08
NanoVibronix, Inc. Announces Completion of Pilot Phase of Clinical Study of UroShield at the University of Michigan Jan 06
NanoVibronix Receives an Additional Deficiency Notice from Nasdaq Due to Non-Compliance with $2.5 Million Stockholders’ Equity Requirement Nov 24
Third quarter 2024 earnings released: US$0.36 loss per share (vs US$0.42 loss in 3Q 2023) Nov 17
Nasdaq Notifies NanoVibronix Regarding Potential Delisting Due to Non-Compliance with Nasdaq Listing Rule 5550(a)(2) Oct 14
NanoVibronix, Inc., Annual General Meeting, Dec 19, 2024 Oct 08
Second quarter 2024 earnings released: US$0.25 loss per share (vs US$0.65 loss in 2Q 2023) Aug 16
Insufficient new directors Jul 01
NanoVibronix, Inc. Announces Commencement of UroShield Clinical Study at the University of Michigan May 23
NanoVibronix Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2) Apr 17 NanoVibronix, Inc. announced delayed annual 10-K filing Apr 02
NanoVibronix Regains Nasdaq Compliance Nov 22
Third quarter 2023 earnings released: US$0.42 loss per share (vs US$0.68 loss in 3Q 2022) Nov 16
NanoVibronix, Inc. Gains Approval for Inclusion of UroShield Products in NHS Prescription Services' Drug Tariff Sep 28 NanoVibronix, Inc. announced that it expects to receive $5 million in funding Aug 31
NanoVibronix, Inc. Applies for Inclusion of Uroshield Products in Nhs Prescription Services' Drug Tariff Aug 29
New minor risk - Share price stability Aug 16
Second quarter 2023 earnings released: US$0.65 loss per share (vs US$0.93 loss in 2Q 2022) Aug 13
NanoVibronix Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market May 26
First quarter 2023 earnings released: US$0.66 loss per share (vs US$0.81 loss in 1Q 2022) May 17
Full year 2022 earnings released: US$3.84 loss per share (vs US$11.35 loss in FY 2021) Apr 18
Most Shareholders Will Probably Find That The Compensation For NanoVibronix, Inc.'s (NASDAQ:NAOV) CEO Is Reasonable Dec 09
NanoVibronix Receives FDA 510(k) Premarket Clearance for PainShield Plus Nov 29
Nanovibronix, Inc. Announces Interim Results of Clinical Study for UroShield Nov 17
Third quarter 2022 earnings released: US$0.034 loss per share (vs US$0.26 loss in 3Q 2021) Nov 16
Insufficient new directors Nov 16
NanoVibronix Receives Extension to Satisfy Nasdaq Price Requirement Oct 20
NanoVibronix receives extension to satisfy Nasdaq bid price requirement Oct 19
Insufficient new directors Sep 29
NanoVibronix rises 27% on approval of Uroshield for sale in UK by NHS internal supply chain contract Sep 23
NanoVibronix, Inc., Annual General Meeting, Sep 14, 2022 Jul 28
Will NanoVibronix (NASDAQ:NAOV) Spend Its Cash Wisely? Jul 08
Insufficient new directors Jul 01
Nanovibronix, Inc. Announces FDA 510(K) Submission for Painshield MD Plus May 05
NanoVibronix, Inc. Adds Additional Product to Federal Supply Schedule Apr 26
NanoVibronix, Inc. announced delayed annual 10-K filing Apr 01
Will NanoVibronix (NASDAQ:NAOV) Spend Its Cash Wisely? Mar 22
NanoVibronix Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market Mar 05
NanoVibronix Files Three U.S. Patent Applications Further Leveraging Its Innovative Surface Acoustic Wave Technology Jan 20
NanoVibronix, Inc. Announces Positive Interim Results from Independent, Real World Patient Study of its UroShield Dec 08
Is NanoVibronix (NASDAQ:NAOV) In A Good Position To Deliver On Growth Plans? Dec 01
Third quarter 2021 earnings released: US$0.25 loss per share (vs US$0.099 loss in 3Q 2020) Nov 18
NanoVibronix, Inc. Launches New, Transdermal Gel Containing Nano-Cannabidiol for the Treatment of Joint Pain and Reducing Inflammation Sep 15
NanoVibronix: Portable Ultrasonic Therapeutic Devices Sep 01
Second quarter 2021 earnings released: US$0.009 loss per share (vs US$0.20 loss in 2Q 2020) Aug 18
NanoVibronix (NASDAQ:NAOV) Is In A Good Position To Deliver On Growth Plans Aug 17
Nanovibronix, Inc Announces That the Therapeutic Goods Administration Aug 12
Nanovibronix Announces Publication of Compelling Study Results for Uroshield in the Journal of Medical & Surgical Urology Jul 23
NanoVibronix Receives Letter from the Listing Qualifications Department of the Nasdaq Stock Market Jun 23
NanoVibronix, Inc. announced delayed 10-Q filing May 18
NanoVibronix Receives Notice from Nasdaq for Not Complying with Continued Listing Rule Apr 30
Nanovibronix Announces Expanded Cms Reimbursement Approval for Painshield Apr 27
NanoVibronix, Inc. announced delayed annual 10-K filing Apr 02
NanoVibronix UroShield Joins PainShield on Federal Supply Schedule, Expanding Access to VA Market Mar 04
NanoVibronix Regains Nasdaq Compliance Feb 04
NanoVibronix, Inc. Enters into an Amended and Restated Distribution Agreement Dec 16
NanoVibronix, Inc. Amends and Expands Distribution Agreement for its Painshield and Painshield Plus with Ultra Pain Products, Inc Dec 13
NanoVibronix announces expansion of distribution pact for its ultrasound devices Dec 11
NanoVibronix, Inc Announces Independent Study Finds Significant Benefits Provided by UroShield Device Dec 03
NanoVibronix secures $6M in equity capital Dec 02
NanoVibronix reports Q3 results Nov 17
Nanovibronix Expands Offerings with Introduction of Painshield Plus Oct 18 NanoVibronix, Inc. Announces Executive Changes
NanoVibronix, Inc. has completed a Follow-on Equity Offering in the amount of $1.794783 million. Sep 26
NanoVibronix's UroShield® Receives U.S. Food and Drug Administration Authorization for Entry into the US Sep 24
NanoVibronix, Inc. has completed a Follow-on Equity Offering in the amount of $3.250001 million. Aug 27
NanoVibronix, Inc. announced delayed 10-Q filing Aug 15
NanoVibronix, Inc. announced that it has received $0.1 million in funding from Aigh Capital Management, LLC Jul 09
NanoVibronix, Inc. announced that it has received $0.2 million in funding from Globis Capital Management, LLC Jul 07
NanoVibronix, Inc. announced delayed 10-Q filing Jun 30 Shareholder Returns NAOV US Medical Equipment US Market 7D 1.8% 3.7% 3.2% 1Y -41.2% 12.4% 24.2%
See full shareholder returns
Return vs Market: NAOV underperformed the US Market which returned 24.2% over the past year.
Price Volatility Is NAOV's price volatile compared to industry and market? NAOV volatility NAOV Average Weekly Movement 15.0% Medical Equipment Industry Average Movement 8.7% Market Average Movement 6.5% 10% most volatile stocks in US Market 18.9% 10% least volatile stocks in US Market 3.2%
Stable Share Price: NAOV's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NAOV's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation.
Show more NanoVibronix, Inc. Fundamentals Summary How do NanoVibronix's earnings and revenue compare to its market cap? NAOV fundamental statistics Market cap US$1.88m Earnings (TTM ) -US$3.09m Revenue (TTM ) US$3.29m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) NAOV income statement (TTM ) Revenue US$3.29m Cost of Revenue US$1.33m Gross Profit US$1.96m Other Expenses US$5.05m Earnings -US$3.09m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.82 Gross Margin 59.62% Net Profit Margin -93.80% Debt/Equity Ratio 0%
How did NAOV perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/20 09:50 End of Day Share Price 2025/01/17 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources NanoVibronix, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Robert Wasserman Dawson James Securities Joseph Gomes Wm Smith & Co. Brian Marckx Zacks Investment Research Inc.
Show 0 more analysts 
